MAM
RAPT

Martingale Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Martingale Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,026
Closed -$597K – 862
2021
Q4 		$597K Buy
+2,026
New +$542K 0.01% 606

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Martingale Asset Management's RAPT Position: Q1 2022 in Review

Martingale Asset Management sold out of RAPT Therapeutics (RAPT) in Q1 2022, closing a stake of 2,026 shares — an estimated $597K sold.

Martingale Asset Management first reported a position in RAPT in Q4 2021 and held it in 1 quarter. The position peaked at $597K in Q4 2021. 85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

  • Martingale Asset Management reported no remaining RAPT Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Martingale Asset Management sold 2,026 RAPT Therapeutics shares in Q1 2022, an estimated $597K.
  • Martingale Asset Management first reported a position in RAPT Therapeutics in Q4 2021 and held it in 1 quarter.
  • Martingale Asset Management's RAPT Therapeutics position peaked at $597K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on Martingale Asset Management's 13F filing for Q1 2022, filed 12 May 2022.